The Translational Potential of Electrochemical DNA-Based Liquid Biopsy

Abstract

Latest technological advancement has tremendously expanded the knowledge on the composition of body fluids and the cancer-associated changes, which has fueled the replacement of invasive biopsies with liquid biopsies by using appropriate specific receptors. DNA emerges as a versatile analytical reagent in electrochemical devices for hybridization-based or aptamer-based recognition of all kind of biomarkers. In this mini review, we briefly introduce the current affordable targets (tumor-derived nucleic acids, circulating tumor cells and exosomes) in body fluids, and then we provide an overview of selected electrochemical methods already applied in clinical samples by dividing them into three large categories according to sample type: red (blood), yellow (urine), and white (saliva and sweat) diagnostics. This review focuses on the hurdles of the complex matrices rather than a comprehensive and detailed revision of the format schemes of DNA-based electrochemical sensing. This diverse perspective compiles some challenges that are often forgotten and critically underlines real sample analysis or clinical validation assays. Finally, the needs and trends to reach the market are briefly outlined.

Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level

“…The detection of CTCs in sarcomas has been proposed to lead to better understanding of the efficacy of therapy and of drug resistance [ 177 , 178 ]. The advent of new technologies to determine and monitor these biological entities in LB [ 179 , 180 , 181 ] holds great promise for developing minimally invasive methods to improve patient care.…”

Biosensor-based assay of exosome biomarker for early diagnosis of cancer

“…Electrochemical biosensors have been applied in exosome detection because of their advantages, such as good adaptability, high sensitivity, facile operation, great convenience, fast, and low cost, making them quickly adapt to clinical settings [75,76]. An electrochemical biosensor is mainly composed of two parts: a bio-recognition element and a transducer.…”

Nucleic Acid Integrated Technologies for Electrochemical Point‐of‐Care Diagnostics: A Comprehensive Review

“…Liquid biopsy is a new detection method of tumor and tumor-derived materials such as circulating tumor DNA (ctDNA) as a type of circulating free DNA (cfDNA) in body fluids. In addition to circulating tumor cells (CTCs), tumor materials may be run with biological fluids containing cell products, nucleic acids, and extracellular vesicles (EV) [90]. Exosomes are known as EVs, and they are very rich in terms of protein and nucleic acid contents serving as specific biomarkers in medical diagnostics.…”